1h Free Analyst Time
The low-concentration atropine market is forecasted to grow by USD 1,039.97 mn during 2023-2028, accelerating at a CAGR of 18.81% during the forecast period. The report on the low-concentration atropine market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of myopia, rising awareness regarding vision care, and growing demand for vision correction among aging population.
The low-concentration atropine market is segmented as below:
By Type
- Atropine sulfate 0.01 percentage
- Atropine sulfate 0.025 percentage
- Atropine sulfate 0.05 percentage
By Application
- Child
- Adult
By Geography
- Asia
- North America
- Europe
- Rest of World (ROW)
The report on the low-concentration atropine market covers the following areas:
- Low-concentration atropine market sizing
- Low-concentration atropine market forecast
- Low-concentration atropine market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Market Segmentation by Application
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global low-concentration atropine market: AdvaCare Pharma, Aurolab, Bausch Lomb Corp., ENTOD INTERNATIONAL, Eyenovia Inc., Gmt Pharma, Grevis Pharmaceuticals Pvt. Ltd., ISKON REMEDIES and GMT, Jawa Pharmaceuticals India Pvt. Ltd., Medizia Biotech, OSRX Inc., Raymed Pharmaceutical Ltd., Santen Pharmaceutical Co. Ltd., Sydnexis Inc., Tache Pharmacy, Taiwan Biotech Co.,Ltd, Vyluma, and Aspire Pharma Ltd.Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is growing number of clinical trials by market vendors.'
According to the report, one of the major drivers for this market is the increasing prevalence of myopia.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AdvaCare Pharma
- Aurolab
- Bausch Lomb Corp.
- ENTOD INTERNATIONAL
- Eyenovia Inc.
- Gmt Pharma
- Grevis Pharmaceuticals Pvt. Ltd.
- ISKON REMEDIES and GMT
- Jawa Pharmaceuticals INDIA Pvt. Ltd.
- Medizia Biotech
- OSRX Inc.
- Raymed Pharmaceutical Ltd.
- Santen Pharmaceutical Co. Ltd.
- Sydnexis Inc.
- Tache Pharmacy
- Taiwan Biotech Co. Ltd
- Vyluma
- Aspire Pharma Ltd
